Immunic
IMUX13.8103.14% ( +0.420 )
Immunic (IMUX)
Immunic, Inc., a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune dise...
- Open
- 13.360
- High
- 14.185
- Low
- 13.180
- Prev. Close
- 13.390
- Volume
- 114.74K
- Turnover
- 1.59M
- Avg Price
- 13.830
- Bid/Ask Ratio
- --
- Amplitude
- 7.51%
- 52wk High
- 15.840
- Volume Ratio
- 0.76
- Turnover Ratio
- 1.02%
Immunic Analyst Rating
View MoreForecast & Rating
Jul 23, 2026Price forecast
$43.22212.98%
Forecast & RatingStrong buy
10analysts
- Strong buy100.00%
- Buy0.00%
- Hold0.00%
- Sell0.00%
- Strong sell0.00%
News
- Tip Ranks · Jul 15 at 03:05 AM
Immunic Updates Corporate Strategy, Highlights Vidofludimus Plans
- PUBT · Jul 14 at 07:19 AM
Immunic publishes investor presentation outlining vidofludimus calcium Phase 3 program in multiple sclerosis
- StockTitan · Jul 8 at 09:30 PM
Immunic to Participate in Investor Conferences in July | IMUX Stock News
- PUBT · Jul 6 at 03:23 PM
Immunic names CEO Erik Lundgren to board after Tamar Howson retirement resignation
- PUBT · Jun 29 at 03:06 PM
Immunic holds annual shareholder meeting, backs 6 million-share increase to equity plan
- Unusual Whales · Jun 10 at 05:33 AM
Immunic to Participate in Investor, Industry and Scientific Conferences in June
